ReviewNature reviews. Gastroenterology & hepatology2019
NAFLD in children: new genes, new diagnostic modalities and new drugs.
Review in Nature reviews. Gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 5 syntheses or guidelines pooled it, 298 citations in OpenAlex.
- The epidemiology of metabolic dysfunction-associated steatotic liver disease among pediatric patients with type 2 diabetes: Systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis.World journal of pediatrics : WJP · 2024Pooled it
- Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis.Systematic reviews · 2023Pooled it
- Pooled it
- Performance of Imaging Techniques in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease in Children: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- Pistacia atlantica sub. Kurdica can improve insulin resistance in patients with non-alcoholic fatty liver disease: a randomized clinical trial.BMC complementary medicine and therapies · 2026Trial
- Pistacia atlantica can improve oxidative status in patients with metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Trial
- Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial.BMC pediatrics · 2024Trial
- Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.Medicina (Kaunas, Lithuania) · 2023Trial
- Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children.Disease markers · 2021Trial
- Redox-Metabolic Crosstalk in Pediatric MASLD: Biomarkers, Mechanisms, and the Emerging Role of Selenium.International journal of molecular sciences · 2026Review
- Lifespan approaches for the prevention and management of steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Waist-to-height ratio as a practical indicator for screening pediatric metabolic dysfunction-associated steatotic liver disease in diverse populations and genetic backgrounds.World journal of pediatrics : WJP · 2026Article
- Serum FAM132A/Adipolin correlates with endothelial dysfunction in children with obesity.Pediatric research · 2026Article
- A comparison of plasma Tsukushi in adolescents with and without metabolic dysfunction-associated steatotic liver disease.Physiological reports · 2026Article
- Retrospective Study of Serum Vitamin D Levels and Metabolic-Associated Fatty Liver Disease in 222 Children and Adolescents Aged 6-18 Years With Obesity.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Management of Childhood Obesity.International journal of molecular sciences · 2026Review
- Elevated gamma glutamyl transferase levels as screening marker of stage 3-4 hepatic fibrosis in youth-onset type 2 diabetes mellitus: a retrospective chart review.BMC endocrine disorders · 2026Article
- Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province.Scientific reports · 2026Article
- Deregulated miR-487b-3p in Patients with Non-Alcoholic Fatty Liver Disease and Its Regulatory Effect on Insulin Resistance.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in children and adolescents. Over the past 5 years, developments have revolutionized our understanding of the genetic factors, natural history, diagnostic modalities and therapeutic targets for this disease. New polymorphisms, such as those in PNPLA3, TM6SF2, MBOAT7 and GCKR, have been identified and used to predict the development and severity of NAFLD in both adults and children, and their interaction with environmental factors has been elucidated. Studies have demonstrated the true burden of paediatric NAFLD and its progression to end-stage liver disease in adulthood. In particular, nonalcoholic steatohepatitis can progress to advanced fibrosis and cirrhosis, emphasizing the importance of early diagnosis. Non-invasive imaging tests, such as transient elastography, will probably replace liver biopsy for the diagnosis of nonalcoholic steatohepatitis and the assessment of fibrosis severity in the near future. The therapeutic landscape is also expanding rapidly with the development of drugs that can modify liver steatosis, inflammation and fibrosis, indicating that pharmacotherapy for NAFLD will become available in the future. In this Review, we summarize current knowledge and new advances related to the pathogenesis and management of paediatric NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.